The effects of novel SGLT2 inhibitors on intestinal smooth muscle activity

A tétel rövid nézete
dc.contributor.advisorUray, Karen
dc.contributor.authorAbilkassym, Dauren
dc.contributor.departmentDE--Természettudományi és Technológiai Kar--Biotechnológiai Intézethu_HU
dc.date.accessioned2021-11-22T08:28:36Z
dc.date.available2021-11-22T08:28:36Z
dc.date.created2021-11-19
dc.description.abstractDue to their unique mechanism of action, inhibitors of the sodium-glucose cotransporter type 2, in addition to glycemic and metabolic effects, have the ability to exert an inhibitory effect on various aspects of the pathogenesis of micro- and macrovascular complications of diabetes mellitus. Further large-scale clinical trials should provide information on which groups of patients with type 2 diabetes mellitus can benefit most from the administration of glyflozins while minimizing the risk of adverse events. Drugs such as BEVA22-2, SzK154 and SzK153 represented their mechanism and sidechains. Which lowers gastrointestinal side effects and improve patient adherence to drug regimens. In type 2 diabetic mice, dapagliflozin therapy reduces arterial stiffness, endothelial dysfunction, and vascular smooth muscle dysfunction, as well as changing the microbiota composition gradually. Collectively, the improvements in generalized vascular function may represent an important mechanism underlying the smooth muscle activity benefits of SGLT2 treatment.hu_HU
dc.description.correctorhbk
dc.description.courseBiochemical engineeringhu_HU
dc.description.degreeBSc/BAhu_HU
dc.format.extent23hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/325232
dc.language.isoenhu_HU
dc.subjectSGLT2 inhibitorshu_HU
dc.subjectSGLThu_HU
dc.subjectSmooth musclehu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleThe effects of novel SGLT2 inhibitors on intestinal smooth muscle activityhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Science and Technology)